You are here

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction

Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, et al.

J Clin Oncol. 2016 Feb 16. [Epub ahead of print]

Editorial comment by Dr Lee:
Apatinib is a small molecule tyrosine kinase inhibitor (TKI) which selectively inhibits vascular endothelial growth factor receptor 2 (VEGFR-2). This randomized, double-blind, placebo-controlled phase III trial shows that apatinib monotherapy significantly improves progression-free survival (median PFS, 2.6 months in the apatinib arm versus 1.8 months in the placebo arm; p < 0.001) and overall survival (median OS, 6.5 months in the apatinib arm versus 4.7 months in the placebo arm; p = 0.0149) in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction after failure with second-line therapy or later. The survival improvements with apatinib therapy is statistically significant but modest, and is consistent with the prior observation with ramucirumab therapy, another VEGF targeting agent, in the second-line setting.

Search this site

Search form

ECCO2017 symposium webcast: Treatment evolution in advanced GI malignancies

Welcome and introduction - Florian Lordick


Subscribe to our E-Alert to keep up to date with the new items in the Resource Centre

Featured Content

New Book Content

This online Resource Centre has been sponsored by Lilly Oncology

Note that Lilly Oncology has no editorial control over the content of this Resource Centre. The Resource Centre and all content therein has been subject to an independent editorial review.